CAM
TRML

Cormorant Asset Management’s Tourmaline Bio TRML Stock Holding History

Cormorant Asset Management’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,250,000
Closed -$28.6M – 63
2024
Q1 		$28.6M Buy
+1,250,000
New +$44.1M 1.26% 26
2023
Q2 		– Sell
-90,065
Closed -$1.69M – 76
2023
Q1 		$1.69M Hold
90,065
– – 0.11% 61
2022
Q4 		$919K Hold
90,065
– – 0.06% 66
2022
Q3 		$2.37M Sell
90,065
-27,407
-23% -$998K 0.17% 58
2022
Q2 		$5.3M Hold
117,472
– – 0.4% 53
2022
Q1 		$11.6M Sell
117,472
-783
-0.7% -$73.3K 0.89% 33
2021
Q4 		$18.1M Sell
118,255
-3,330
-3% -$493K 1.08% 27
2021
Q3 		$16.3M Hold
121,585
– – 0.66% 40
2021
Q2 		$17.3M Buy
+121,585
New +$18.6M 0.59% 46

Other funds holding TRML

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Cormorant Asset Management's TRML Position: Q2 2024 in Review

Cormorant Asset Management sold out of Tourmaline Bio (TRML) in Q2 2024, closing a stake of 1,250,000 shares — an estimated $28.6M sold.

Cormorant Asset Management first reported a position in TRML in Q2 2021 and held it in 9 quarters. The position peaked at $28.6M in Q1 2024. 84 funds tracked by Wall St. Rank hold TRML as of Q2 2024.

  • Cormorant Asset Management reported no remaining Tourmaline Bio position as of Q2 2024 after selling out during the quarter.
  • Cormorant Asset Management sold 1,250,000 Tourmaline Bio shares in Q2 2024, an estimated $28.6M.
  • Cormorant Asset Management first reported a position in Tourmaline Bio in Q2 2021 and held it in 9 quarters.
  • Cormorant Asset Management's Tourmaline Bio position peaked at $28.6M in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Tourmaline Bio as of Q2 2024.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.